Communiqué de presse Archives

Novigenix presenting at BioTechX Europe 2023, “AI- Powered RNA Analytics to Drive Innovation in Cancer Therapy through Liquid Biopsy”, Oct 5th, 2:50 PM

By admin web|2023-10-04T13:28:49+02:004 October 2023|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

Novigenix is a pioneering, precision medicine biotech, focusing on AI-RNA analysis to improve treatment outcomes for cancer patients. Our immuno- transcriptomic solutions make earlier detection of disease possible, capture the immune profile of the patient in order to predict likely response to treatment, and enable novel drug development. The Novigenix platform is optimized for whole-blood

Novigenix Reports Interim European Validation Data on its New NGS-based Whole Blood RNA Signature for detection of Advanced Colorectal Adenomas

By admin web|2023-06-30T09:38:07+02:0030 June 2023|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

LAUSANNE, SWITZERLAND – Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced presentation of its interim European validation data for its whole blood RNA signature for early detection of pre-cancerous colorectal cancer legions (Advanced Colorectal Adenomas). The data is presented at the European Society

Novigenix Appoints Dr. Pedro Romero as Director of Medical & Scientific Affairs

By Sahar Hosseinian|2023-05-15T11:51:50+02:0015 May 2023|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

LAUSANNE, SWITZERLAND – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced appointment of Dr. Pedro Romero as Director of Medical & Scientific Affairs. Dr. Romero has previously served on the Medical Advisory Board of Novigenix and brings over three decades of experience in immunology and immune

Novigenix announces first closing of its $20M Series B

By Sahar Hosseinian|2023-05-15T11:44:51+02:0016 November 2022|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

Expansion of Biopharma precision solutions in the field of Immuno-Oncology LAUSANNE, SWITZERLAND - November 15, 2022 – Novigenix SA, a leading data-driven precision medicine biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced successful first closing of its $20 million Series B financing round with participation from existing and new investors. Novigenix‘s

Novigenix announces discovery of liquid biopsy immunotherapy response biomarkers in metastatic Melanoma

By Sahar Hosseinian|2022-09-09T07:31:43+02:009 September 2022|Communiqué de presse, News Novigenix|

New LITOseek biomarkers presented at ESMO have identified upregulation of ribosomal biogenesis and TCR signaling with downregulation of interferon gene clusters in responsive patients LAUSANNE, SWITZERLAND - September 9th, 2022 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions today announced discovery of new Immuno-Transcriptomic signatures for prediction of

Novigenix and Philips Sign Technology License Agreement for Prostate Cancer Precision Oncology Products

By Sahar Hosseinian|2022-03-08T22:00:36+02:009 March 2022|Communiqué de presse, News Novigenix|

New precision solutions may be accessible on Philips IntelliSpace Precision Medicine Platform LAUSANNE, SWITZERLAND - March 8, 2022 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced a Technology License Agreement with Royal Philips (‘Philips’) for development of new tissue biopsy Prostate cancer (PCa) Immuno-Transcriptomic tests to

Co-founder and CTO Dr Sahar Hosseinian shares her successful path to entrepreneurship in an interview by Biopôle Life Science Campus in Lausanne.

By Sahar Hosseinian|2022-02-04T12:48:37+02:004 February 2022|Communiqué de presse, News Novigenix|

LAUSANNE, SWITZERLAND – February 1st, 2022 – Novigenix Co-founder and CTO Dr Sahar Hosseinian shares her successful path to founding Novigenix and entrepreneurship in an interview by Lausanne’s Life Science Hub Biopôle. “I met two biologists who were hugely inspiring and had amazing data that leveraged the host response in cancer patients to save

Novigenix expands Advisory Board with influential scientific and commercial opinion leaders

By Sahar Hosseinian|2021-10-27T12:33:35+02:0027 October 2021|Communiqué de presse, News Novigenix|

Novigenix expands Advisory Board with influential scientific and commercial opinion leaders LAUSANNE, SWITZERLAND - October 26th, 2021 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions is thrilled to announce the nomination of three leading figures to the Advisory Board. "We are pleased and honored to welcome Professor

Novigenix and Radboud University Medical Center Discover the First Blood-Based ImmunoTranscriptomic biomarkers for Response to Anti-PD-1 therapy

By Sahar Hosseinian|2022-01-25T11:48:18+02:0028 September 2021|Communiqué de presse, News Novigenix|

Publication in Cancers Journal Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 LAUSANNE, SWITZERLAND - September 23rd, 2021 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced release of the article: “Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell

Novigenix Announces Election of Dr. Miro Venturi to its Board of Directors

By Sahar Hosseinian|2022-02-04T12:43:38+02:0031 August 2021|Communiqué de presse, News Novigenix|

Company expands precision medicine solutions for drug development and clinical utility programs. LAUSANNE, SWITZERLAND - August 31, 2021 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced election of Dr. Miro Venturi to its Board of Directors. Dr. Venturi is currently Group CEO of Sintetica SA,